Digital Aria Co Ltd (115450) - Total Liabilities

Latest as of December 2025: ₩54.79 Billion KRW ≈ $37.13 Million USD

Based on the latest financial reports, Digital Aria Co Ltd (115450) has total liabilities worth ₩54.79 Billion KRW (≈ $37.13 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 115450 net assets growth trend to track the company's year-over-year net asset growth rate.

Digital Aria Co Ltd - Total Liabilities Trend (2011–2025)

This chart illustrates how Digital Aria Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Digital Aria Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Digital Aria Co Ltd Competitors by Total Liabilities

The table below lists competitors of Digital Aria Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Sterling Tools Limited
NSE:STERTOOLS
India Rs3.01 Billion
ZenaTech Inc.
NASDAQ:ZENA
USA $31.83 Million
Control Print Limited
NSE:CONTROLPR
India Rs985.53 Million
Modetour Network Inc
KQ:080160
Korea ₩138.07 Billion
Polytec Holding AG
VI:PYT
Austria €256.24 Million
Kirloskar Electric Company Limited
NSE:KECL
India Rs4.84 Billion
ZJK Industrial Co., Ltd
NASDAQ:ZJK
USA $26.87 Million
PT Janu Putra Sejahtera Tbk
JK:AYAM
Indonesia Rp287.21 Billion

Liability Composition Analysis (2011–2025)

This chart breaks down Digital Aria Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Digital Aria Co Ltd worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.84 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.36 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.24 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Digital Aria Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Digital Aria Co Ltd (2011–2025)

The table below shows the annual total liabilities of Digital Aria Co Ltd from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 ₩54.79 Billion
≈ $37.13 Million
-12.09%
2024-12-31 ₩62.33 Billion
≈ $42.24 Million
+112.90%
2023-12-31 ₩29.28 Billion
≈ $19.84 Million
-58.73%
2022-12-31 ₩70.94 Billion
≈ $48.07 Million
-0.14%
2021-12-31 ₩71.03 Billion
≈ $48.14 Million
+117.99%
2020-12-31 ₩32.58 Billion
≈ $22.08 Million
-56.89%
2019-12-31 ₩75.58 Billion
≈ $51.22 Million
+93.83%
2018-12-31 ₩38.99 Billion
≈ $26.43 Million
+60.68%
2017-12-31 ₩24.27 Billion
≈ $16.45 Million
+36.58%
2016-12-31 ₩17.77 Billion
≈ $12.04 Million
-12.31%
2015-12-31 ₩20.26 Billion
≈ $13.73 Million
-43.71%
2014-12-31 ₩36.00 Billion
≈ $24.40 Million
+36.85%
2013-12-31 ₩26.31 Billion
≈ $17.83 Million
-34.61%
2012-12-31 ₩40.23 Billion
≈ $27.26 Million
-8.26%
2011-12-31 ₩43.85 Billion
≈ $29.72 Million
--

About Digital Aria Co Ltd

KQ:115450 Korea Biotechnology
Market Cap
$98.99 Million
₩146.07 Billion KRW
Market Cap Rank
#19158 Global
#909 in Korea
Share Price
₩1657.00
Change (1 day)
+9.01%
52-Week Range
₩1451.00 - ₩3980.00
All Time High
₩25764.90
About

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrica… Read more